Pharmacokinetics of single and multiple doses of clobazam in humans.
1. The pharmacokinetics of clobazam and its biotransformation product N-desmethylclobazam were investigated after single and multiple doses in normal subjects. 2. The relevant physicochemical properties of clobazam were measured and are presented. Different assay methods (radiochemical, fluorimetric and gas chromatographic) were applied and the results correlated. 3. After single doses the pharmacokinetic profile of clobazam includes time to peak levels 1--4 h after dosing, peak levels increasing linearly with the logarithm of dose, and terminal half-lives of about 18 hours. At least 87% of an oral dose is absorbed, as indicated by urinary recovery of labelled material. 4. In multiple-dose studies unchanged clobazam levelled off at minimum steady-state concentrations within one week of dosing. During 28 d of medication N-desmethylclobazam accumulated to near steady-state levels about eight times higher than those of the unchanged compound. 5. No pharmacokinetic interactions were discovered between clobazam and the antidepressant nomifensine.
D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000378:metabolism*; D001569:Benzodiazepines; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003640:Dealkylation; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D009627:Nomifensine / Q000378:metabolism
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D009627:Nomifensine